Evidence map›Paper›PMID 34204564›Full record

ReviewMolecules (Basel, Switzerland)2021

First-in-Class Phosphorus Dendritic Framework, a Wide Surface Functional Group Palette Bringing Noteworthy Anti-Cancer and Anti-Tuberculosis Activities: What Lessons to Learn?

Serge Mignani, Jérôme Bignon, Xiangyang Shi, Jean-Pierre Majoral

Abstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Advanced Macromolecular Architectures via Inorganic Polymers.Macromolecular rapid communications · 2026
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Serge MignaniLaboratoire de Chimie et de Biochimie Pharmacologiques et Toxicologique, PRES Sorbonne Paris Cité, CNRS UMR 860, Université Paris Descartes, 45, Rue des Saints Peres, 75006 Paris, France.
Jérôme BignonInstitut de Chimie des Substances Naturelles du CNRS, 91198 Avenue de la Terrasse, CEDEX, Gif-sur-Yvette, 91190 Paris, France.
Xiangyang ShiCollege of Chemistry, Chemical Engineering and Biotechnology, Donghua University, Shanghai 201620, China.ORCID 0000-0001-6785-6645
Jean-Pierre MajoralLaboratoire de Chimie de Coordination du CNRS, 205 Route de Narbonne, BP 44099, CEDEX 4, 31077 Toulouse, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Based on phenotypic screening, the major advantages of phosphorus dendrimers and dendrons as drugs allowed the discovery of new therapeutic applications, for instance, as anti-cancer and anti-tuberculosis agents. These biological activities depend on the nature of the chemical groups (neutral or cationic) on their surface as well as their generation. As lessons to learn, in the oncology domain, the increase in the generation of metallo-dendrimers is in the same direction as the anti-proliferative activities, in contrast to the development of polycationic dendrimers, where the most potent anti-tuberculosis phosphorus dendrimer was observed to have the lowest generation (G0). The examples presented in this original analysis of phosphorus dendrimers and dendrons provide support for the lessons learned and for the development of new nanoparticles in nanomedicine.

Indexed as

AnimalsAntineoplastic AgentsAntitubercular AgentsDendrimersHumansMolecular StructureNanomedicineNanoparticlesNeoplasmsPhosphorusTuberculosisAntineoplastic AgentsAntitubercular AgentsDendrimersPhosphorusanti-cancer agentsanti-tubercular agentsnanomedicinephosphorus dendrimersphosphorus dendrons

Identifiers

PMID34204564
PMCPMC8234563

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.